Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non Operating Income (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Non Operating Income for 8 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 52.61% year-over-year to $1.5 million, compared with a TTM value of $10.1 million through Dec 2025, down 33.57%, and an annual FY2025 reading of $10.1 million, down 33.56% over the prior year.
  • Non Operating Income was $1.5 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $3.2 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $6.9 million in Q4 2023 and bottomed at -$564000.0 in Q1 2022.
  • Average Non Operating Income over 5 years is $2.0 million, with a median of $2.5 million recorded in 2023.
  • The sharpest move saw Non Operating Income crashed 2281.82% in 2021, then soared 1340.19% in 2023.
  • Year by year, Non Operating Income stood at -$524000.0 in 2021, then skyrocketed by 295.61% to $1.0 million in 2022, then skyrocketed by 571.32% to $6.9 million in 2023, then crashed by 53.29% to $3.2 million in 2024, then crashed by 52.61% to $1.5 million in 2025.
  • Business Quant data shows Non Operating Income for ARCT at $1.5 million in Q4 2025, $3.2 million in Q3 2025, and $2.6 million in Q2 2025.